Role of lactoferrin in preventing preterm birth and pregnancy complications: a systematic review and meta-analysis.

To report the role of lactoferrin supplementation for the prevention of preterm birth (PTB) in women at risk.Pubmed and Embase databases were searched. Inclusion criteria were studies exploring maternal and perinatal outcomes in women at high-risk for preterm birth receiving compared to those not receiving lactoferrin during pregnancy. The primary outcome preterm PTB <37 weeks; the secondary outcomes were gestational age at birth, PTB< 34 and 28 weeks, preterm premature rupture of the membranes (PPROM), chorioamnionitis and admission to neonatal intensive care unit. Random effect meta-analyses were used to analyse the data.Six studies (333 pregnancies) were included. Overall, women taking lactoferrin had a lower risk of PTB < 37 weeks of gestation with an OR of 0.43 (95% CI 0.2-0.9). Likewise, gestational age at delivery was higher in women taking compared to those not taking lactoferrin (MD: 0.46 weeks, SD: 0.17, p= 0.006). The other included studies explored the role of lactoferrin in affecting the inflammatory profile in the amniotic fluid of women undergoing invasive test, without reporting its actual role in preventing PTB.Prophylactic administration of lactoferrin can reduce the risk of PTB in women at risk. Further large and adequately powered randomized trial are needed in order to elucidate the actual role of lactoferrin in reducing the risk of preterm birth and in affecting perinatal outcomes in women at risk.